Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

p53: 800 million years of evolution and 40 years of discovery
Arnold J. Levine
Nature reviews. Cancer (2020) Vol. 20, Iss. 8, pp. 471-480
Closed Access | Times Cited: 603

Showing 1-25 of 603 citing articles:

LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer
Yue‐Tao Tan, Jin‐Fei Lin, Ting Li, et al.
Cancer Communications (2020) Vol. 41, Iss. 2, pp. 109-120
Open Access | Times Cited: 499
Drugging p53 in cancer: one protein, many targets
Ori Hassin, Moshe Oren
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 127-144
Open Access | Times Cited: 420
Targeting p53 pathways: mechanisms, structures and advances in therapy
Haolan Wang, Ming Guo, Hudie Wei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 389
p53 in ferroptosis regulation: the new weapon for the old guardian
Yanqing Liu, Wei Gu
Cell Death and Differentiation (2022) Vol. 29, Iss. 5, pp. 895-910
Open Access | Times Cited: 351
Biologically informed deep neural network for prostate cancer discovery
Haitham Elmarakeby, Justin H. Hwang, Rand Arafeh, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 348-352
Open Access | Times Cited: 272
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Zhen Luo, Mingfu Tian, Ge Yang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 244
Sex disparities matter in cancer development and therapy
Sue Haupt, Franco Caramia, Sabra L. Klein, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 6, pp. 393-407
Open Access | Times Cited: 222
Mutant p53 in Cancer Progression and Targeted Therapies
Gaoyang Zhu, Chaoyun Pan, Jin‐Xin Bei, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 191
The complexity of p53-mediated metabolic regulation in tumor suppression
Yanqing Liu, Wei Gu
Seminars in Cancer Biology (2021) Vol. 85, pp. 4-32
Open Access | Times Cited: 179
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 148
Cuproptosis: p53-regulated metabolic cell death?
Xiong Chen, Hong Ling, Qian Hao, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 4, pp. 876-884
Open Access | Times Cited: 144
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis
Raymond Chen, Charles A. Ishak, Daniel D. De Carvalho
Cancer Discovery (2021) Vol. 11, Iss. 11, pp. 2707-2725
Open Access | Times Cited: 129
Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes
Evgeni Gusev, Alexey Sarapultsev
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7910-7910
Open Access | Times Cited: 114
Understanding the complexity of p53 in a new era of tumor suppression
Yanqing Liu, Zhenyi Su, Omid Tavana, et al.
Cancer Cell (2024) Vol. 42, Iss. 6, pp. 946-967
Open Access | Times Cited: 111
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 440-462
Closed Access | Times Cited: 99
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Naval Daver, Abhishek Maiti, Tapan M. Kadia, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2516-2529
Open Access | Times Cited: 96
Should mutant TP53 be targeted for cancer therapy?
Zilu Wang, Andreas Strasser, Gemma L. Kelly
Cell Death and Differentiation (2022) Vol. 29, Iss. 5, pp. 911-920
Open Access | Times Cited: 94
Targeting immunogenic cell stress and death for cancer therapy
Lorenzo Galluzzi, Emma Guilbaud, Darby Schmidt, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 6, pp. 445-460
Open Access | Times Cited: 90
TRIM family contribute to tumorigenesis, cancer development, and drug resistance
Ning Huang, Xiaolin Sun, Peng Li, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 86
Foundations of plasmas for medical applications
Thomas von Woedtke, Mounir Laroussi, Matteo Gherardi
Plasma Sources Science and Technology (2022) Vol. 31, Iss. 5, pp. 054002-054002
Open Access | Times Cited: 82
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
Mehrnoosh Tashakori, Tapan M. Kadia, Sanam Loghavi, et al.
Blood (2022) Vol. 140, Iss. 1, pp. 58-72
Open Access | Times Cited: 74
The ARTS of p53-dependent mitochondrial apoptosis
Qian Hao, Jiaxiang Chen, Hua Lu, et al.
Journal of Molecular Cell Biology (2022) Vol. 14, Iss. 10
Open Access | Times Cited: 73
FOXO transcription factors as mediators of stress adaptation
Maria J. Rodríguez Colman, Tobias B. Dansen, Boudewijn Burgering
Nature Reviews Molecular Cell Biology (2023) Vol. 25, Iss. 1, pp. 46-64
Closed Access | Times Cited: 65
Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1210-1229
Open Access | Times Cited: 60
The DNA Damage Response and Inflammation in Cancer
Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1521-1545
Open Access | Times Cited: 57
Page 1 - Next Page

Scroll to top